Prescriber Scope of Practice for Weight Loss/GLP-1 in California

If you’re a psychiatrist or psychiatric nurse practitioner exploring weight management as an income stream or patient service—whether to address medication-related weight gain or tap into the booming GLP-1 market—you’re probably wondering: Can I legally prescribe weight-loss medications via telehealth? What are the compliance landmines?

The short answer: Yes, psychiatrists (MDs/DOs) can prescribe weight-loss drugs including GLP-1s and phentermine through telemedicine in most states—but the rules vary wildly by state, your provider type, and whether the medication is a controlled substance. As of early 2026, federal telehealth flexibilities for controlled substances remain extended through December 31, 2026, but states like New York have reimposed strict in-person requirements, while Florida and Texas allow remote prescribing under specific protocols.

Let’s cut through the regulatory noise and focus on what actually matters for your practice.

The Federal Picture: DEA Telehealth Rules Are Extended (For Now)

Under normal circumstances, the Ryan Haight Act requires an in-person medical evaluation before prescribing any controlled substance via telemedicine. But COVID changed everything. The DEA waived this requirement during the public health emergency, and as of January 2026, HHS and DEA extended these telehealth flexibilities through the end of 2026 to prevent a ‘telehealth cliff’ while permanent rules are developed.

What this means for you:

• Through December 31, 2026, you can prescribe controlled substances (including Schedule IV phentermine) via telehealth to new patients without an initial in-person visit—at the federal level
• GLP-1 agonists like semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are not controlled substances, so they’re prescribable via telehealth with no federal restrictions beyond standard prescribing protocols
• The DEA is working on permanent telemedicine regulations that will likely require special registrations or impose limits (e.g., initial 30-day supplies for Schedule II stimulants)

The catch: Federal law sets the floor, not the ceiling. States can—and do—impose stricter rules.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

The State Minefield: Where You Can (and Can’t) Prescribe Weight Loss Meds via Telehealth

New York: Back to In-Person for Controlled Substances

New York’s Department of Health reinstated strict rules in May 2025: No controlled substance prescriptions via telehealth unless you’ve conducted at least one in-person exam of that patient (or meet narrow exceptions—like covering for a colleague who saw the patient in person, or prescribing a max 5-day emergency supply to an established patient).

For weight loss:

• GLP-1s (semaglutide, tirzepatide): No problem—prescribe via video consult
• Phentermine (Schedule IV): You need an in-person visit first, or coordinate with another NY provider who’s examined the patient in the past 12 months and shares records

Why it matters: If you’re building a New York telehealth weight-loss practice around phentermine, you’ll need a hybrid model—partner with local clinics for initial visits, or focus exclusively on non-controlled options.

NY also requires:

• PDMP check within 24 hours before any Schedule II–IV prescription
• Electronic prescribing for all medications (mandatory EPCS for controlled substances)

Florida: Telehealth-Friendly for Weight Loss (With Strict Protocols)

Florida explicitly allows telehealth for obesity treatment—but you must follow the Board of Medicine’s obesity prescribing standards to the letter:

Requirements:

• Patient must have BMI ≥30 (or ≥27 with comorbidities)
• Documented initial evaluation (can be via telehealth) including history, physical exam, necessary tests
• Written informed consent outlining risks of weight-loss medications
• Re-evaluation every 3 months minimum if patient continues therapy
• Provide Florida’s ‘Weight-Loss Consumer Bill of Rights’ to each patient

Controlled substances:

• Florida prohibits teleprescribing Schedule II controlled substances except for psychiatric treatment (good news for ADHD stimulants, irrelevant for weight loss)
• Phentermine (Schedule IV) is allowed via telehealth—no in-person requirement
• Must check Florida’s E-FORCSE PDMP before prescribing any controlled substance to patients age 16+

The opportunity: Florida’s large, weight-conscious population and telehealth-permissive laws make it attractive—but the state has a history of cracking down on ‘pill mills,’ so documentation and quarterly follow-ups aren’t optional.

California: Telehealth Exam Counts, But Watch Scope and Corporate Practice

California allows telehealth exams to satisfy the ‘appropriate prior examination’ requirement for prescribing. No state-level ban on controlled substance teleprescribing.

Key compliance points:

• Telehealth consent required (B&P Code §2290.5)—document patient’s verbal or written consent for telehealth services
• CURES PDMP check before first prescription of any Schedule II–IV medication, then every 4 months for ongoing therapy
• All prescriptions must be e-prescribed (mandatory since 2022)

Scope considerations:

• Psychiatrists (MDs): Full authority to prescribe weight-loss meds, but must meet standard of care (document BMI, comorbidities, informed consent)
• PMHNPs: Tricky. California NPs practice under ‘Standardized Procedures’ with physician supervision unless they qualify for independent practice under AB 890 (requires 3+ years experience, certification in population focus). Even with independent practice authority, a psych NP prescribing solely for obesity may be practicing outside their licensed scope—consider physician collaboration or dual certification
• Corporate Practice of Medicine: Only physician-owned entities can provide medical services in CA. If you’re joining a telehealth platform or opening a clinic, the ownership structure must comply

Economic note: Medi-Cal will stop covering GLP-1s for weight loss effective January 2026—cash-pay telehealth models will dominate.

Texas: Telehealth Permitted, But Requires Live Interaction and PMP Checks

Texas allows telehealth prescribing of controlled substances (including phentermine) with no in-person requirement, but you must establish a valid patient relationship via live video or store-and-forward technology combined with audio.

Requirements:

• Synchronous audiovisual interaction (or equivalent clinical information exchange)
• Check Texas PMP (AWARxE) before prescribing controlled substances—while not statutorily required for phentermine specifically, best practice (and most clinic policies) mandate it
• Document and provide follow-up care instructions; with patient consent, send report to primary care provider within 72 hours

NP/PA scope:

• All NPs and PAs require a Prescriptive Authority Agreement with a Texas-licensed physician
• NPs/PAs cannot prescribe Schedule II independently (only in hospital/hospice settings)
• For phentermine (Schedule IV), they can prescribe if the delegating physician includes it in the agreement

Market reality: High obesity rates = high demand. But Texas medical board and AG have sanctioned clinics for misleading advertising and improper delegation—operate transparently.

Pennsylvania: Defers to Federal Law (For Now)

Pennsylvania has no comprehensive telehealth statute—relies on professional standards and existing regulations.

Current status:

• No state-level in-person requirement for controlled substance prescribing
• Under federal DEA extension, can prescribe phentermine and GLP-1s via telehealth
• PA PDMP must be checked before first opioid or benzodiazepine prescription, and each time for ongoing therapy; recommended for all controlled substances

NP/PA scope:

• CRNPs require collaborative agreement with physician to prescribe (including weight-loss meds if delegated)
• No independent practice for NPs in PA

Practical tip: Pennsylvania is watching how telehealth evolves nationally. Practice conservatively—thorough documentation, clear justification for prescribing, PDMP checks—to stay ahead of potential future restrictions.

Illinois: Telehealth-Friendly with Full Practice Authority for Experienced NPs

Illinois explicitly permits telehealth to establish patient relationships and prescribe medications, including controlled substances, with no in-person mandate.

Key points:

• Full Practice Authority (FPA) available for APRNs with 4,000+ clinical hours and additional training—allows independent prescribing of all medications including controlled substances
• PMPnow (Illinois PDMP) must be checked for each Schedule II narcotic prescription; recommended for all controlled substances
• All controlled substance prescriptions must be e-prescribed (effective Jan 2023)

Market opportunity: Illinois’s progressive telehealth policies and high prevalence of obesity/diabetes make it attractive for telehealth weight management. Chicago-area patients are tech-savvy and comfortable with virtual care.

Psychiatrist vs. PMHNP: Who Can Prescribe What?

Psychiatrists (MD/DO)

Legal authority: Full prescribing authority for weight-loss medications (GLP-1s, phentermine, etc.) in all states—your medical license isn’t specialty-restricted.

Practical considerations:

• Competence requirement: You must practice within your clinical competence. If you’re prescribing obesity medications, you’re expected to know the standard of care—BMI eligibility criteria, contraindications, monitoring parameters (blood pressure, glucose, thyroid function if indicated)
• Documentation: State boards expect the same rigor as an obesity medicine specialist—document weight history, comorbidities, diet/exercise counseling, informed consent
• Liability: Psychiatrists prescribing weight-loss meds have faced scrutiny when patients develop adverse events (e.g., cardiovascular complications from phentermine in a patient with undiagnosed hypertension). Document thoroughly and consider obtaining additional training or certification (American Board of Obesity Medicine offers a diplomate program)

Why psychiatrists are well-positioned:

• You already manage medication-related weight gain (antipsychotics, mood stabilizers)
• You’re comfortable with controlled substances and PDMP monitoring
• You can address psychiatric comorbidities (binge eating disorder, depression) that complicate weight loss

Psychiatric Nurse Practitioners (PMHNPs)

Legal authority: More limited and state-dependent.

Scope-of-practice concerns:

• PMHNPs are certified to treat mental health conditions—not metabolic disorders
• Prescribing solely for obesity may be viewed by state nursing boards as practicing outside your licensed scope, especially in states that define NP practice narrowly
• Physician collaboration often required: In states like Texas and Florida (for NPs without autonomous practice), you’d need a collaborating physician—ideally a family medicine or internal medicine doc, not another psychiatrist—to supervise weight-loss treatment

States with more flexibility:

• California (with AB 890 independent practice): Family NPs can treat obesity independently if they meet criteria; psych NPs would still face scope questions
• Illinois (with Full Practice Authority): A PMHNP with FPA could theoretically prescribe weight-loss meds, but prudent practice would involve consultation or dual certification

Practical path forward for PMHNPs:

• Focus on GLP-1s for patients with psychiatric medication-related weight gain (within your scope)
• Partner with a physician colleague to co-manage obesity treatment
• Consider obtaining additional certification (e.g., obesity medicine training) to strengthen your competency argument

The Economics: What Telehealth Weight Loss Actually Costs

Most providers get into telehealth weight loss because they hear it’s ‘easy money’—low overhead, high demand, $200–300 per patient visit. But here’s the reality check on patient acquisition costs and what platforms like Klarity actually offer.

The DIY Marketing Math

If you’re building your own telehealth weight-loss practice and marketing it yourself, here’s what patient acquisition actually costs:

SEO (Search Engine Optimization):

• Timeline: 6–12 months of consistent content, link-building, and technical optimization before meaningful patient flow
• Cost: $2,000–5,000/month for an experienced agency, or hundreds of unpaid hours if you DIY
• Reality: Most solo providers don’t have the expertise or patience—by month 3, you’re still on page 4 of Google

Google Ads (PPC):

• Cost per click: $15–40+ for mental health and weight loss keywords
• Conversion rate: 2–5% of clicks turn into booked appointments (most bounce after seeing pricing or realizing you’re out-of-network)
• Real cost per booked patient: $200–400+ when you factor in wasted clicks, testing/optimization time, and no-show rates from cold leads

Directory Listings (Psychology Today, Zocdoc):

• Monthly fees: $30–100+ for basic listings
• Competition: You’re one of hundreds of providers on the same search result page
• Zocdoc: Charges $35–100+ per booking plus monthly subscription—total cost adds up quickly

Total monthly marketing spend for a meaningful patient flow: $3,000–5,000+ with zero guaranteed results. You’re gambling that your SEO will eventually rank, your ads will convert, and your directory profile will stand out.

The Klarity Economic Model

Klarity uses a pay-per-appointment model similar to Zocdoc, but with a critical difference: you only pay a standard listing fee when a pre-qualified, matched patient books with you.

What you’re actually paying for:

• No upfront marketing spend or monthly subscriptions eating into your cash flow while you wait for patients
• Pre-qualified patients already matched to your specialty (weight loss, psychiatry, etc.) and availability—no wasted time fielding inquiries from people who can’t afford your services or live three states away
• Zero ad spend risk—you’re not burning $2,000/month testing Google Ads that might not convert
• Built-in telehealth infrastructure—no separate platform costs for video visits, EHR, or e-prescribing integrations
• Both insurance and cash-pay patient flow, depending on your preference

The ROI comparison:

• DIY approach: Spend $3,000–5,000/month, hope you get 10–15 qualified new patients (if your marketing works), worry about no-shows and unqualified leads
• Klarity approach: Pay only when a patient books—guaranteed ROI because you’re not paying for clicks or impressions that go nowhere

For providers starting out or scaling: A platform that handles patient acquisition removes the single biggest barrier to growth. Instead of spending your evenings learning Google Analytics and writing blog posts, you’re seeing patients and earning.

Controlled Substance Prescribing: What You Must Know

Phentermine (Schedule IV)

Federal status: Controlled substance, subject to DEA telehealth rules (currently waived through 2026)

State variations:

• New York: In-person exam required before prescribing
• Florida, Texas, California, Pennsylvania, Illinois: Allowed via telehealth under current rules

PDMP requirements:

• California: Check CURES before first prescription, then every 4 months
• Florida: Check E-FORCSE before prescribing to anyone age 16+
• Texas: Best practice to check Tx PMP (not statutorily required for phentermine specifically, but standard of care)
• New York: Check within 24 hours before prescribing
• Pennsylvania: Check before first prescription; required at each refill for benzos/opioids, recommended for all controlled substances
• Illinois: Not mandated for non-narcotic controlled substances, but prudent practice

Clinical considerations:

• Stimulant effects—can worsen anxiety, trigger mania in bipolar patients, elevate blood pressure
• Contraindicated in patients with cardiovascular disease, hyperthyroidism, glaucoma, or history of substance abuse
• Document: Cardiovascular assessment (BP, pulse), psychiatric history, substance use history

GLP-1 Agonists (Semaglutide, Tirzepatide)

Federal status: Not controlled substances—no DEA restrictions

State telehealth requirements: Must meet standard of care for prescribing (appropriate evaluation via video, informed consent, monitoring plan)

Clinical monitoring:

• GI side effects (nausea, vomiting, diarrhea)—start low, titrate slowly
• Thyroid considerations—black box warning for medullary thyroid carcinoma risk; screen for personal/family history
• Pancreatitis risk—educate patients on symptoms, monitor amylase/lipase if indicated
• Hypoglycemia risk if patient is on other diabetes meds or has psych meds affecting glucose metabolism

Insurance/access issues:

• Many commercial insurers cover GLP-1s for diabetes (Ozempic, Mounjaro) but not obesity (Wegovy, Zepbound) unless BMI >30 with comorbidity
• California Medi-Cal stops coverage for weight loss GLP-1s in January 2026
• Cash-pay pricing: $900–1,200/month without insurance—many patients can’t afford long-term

Compliance Checklist: How to Stay Legal

Pre-Prescription:

• [ ] Verify patient is located in a state where you’re licensed
• [ ] Conduct synchronous audio-video evaluation (or meet state-specific telehealth standards)
• [ ] Document thorough history: weight trajectory, previous weight loss attempts, comorbidities (diabetes, hypertension, dyslipidemia, sleep apnea), psychiatric history, substance use history
• [ ] Obtain and document telehealth consent (required in CA, IL, recommended everywhere)
• [ ] Obtain obesity treatment informed consent (required in FL, best practice everywhere)—outline medication risks, alternatives, expected outcomes
• [ ] Check state PDMP if prescribing controlled substances (timing requirements vary—see state chart above)

Clinical Documentation:

• [ ] BMI calculation with documented height/weight (or patient-reported if telehealth)
• [ ] Cardiovascular assessment (baseline BP, pulse; EKG if indicated for phentermine)
• [ ] Lab work if indicated (TSH for thyroid, A1C for diabetes, lipid panel)
• [ ] Diet/exercise counseling documented (many states require this)
• [ ] Psychiatric evaluation if history of mood disorders or eating disorders

Prescribing:

• [ ] E-prescribe (mandatory in CA, NY, IL, TX for controlled substances)
• [ ] Include diagnosis code (E66.9 for obesity, F50.81 for binge eating if applicable)
• [ ] Set appropriate quantity/duration (avoid ‘indefinite’ refills on controlled substances)
• [ ] Document PDMP check in patient record

Follow-Up:

• [ ] Schedule re-evaluation (Florida: every 3 months minimum; best practice: monthly initially for dose titration)
• [ ] Coordinate with patient’s PCP (Texas: send report within 72 hours if patient consents; best practice everywhere)
• [ ] Monitor for adverse effects and efficacy (weight loss progress, side effects, medication adherence)
• [ ] Reassess need for continuation (obesity meds aren’t meant to be indefinite—evaluate whether patient can transition to maintenance without medication)

State-Specific Quick Reference: Weight Loss Teleprescribing Rules

The Bottom Line: Should You Add Weight Loss to Your Practice?

You should consider it if:

• You’re already managing medication-related weight gain in your psychiatric patients and want to formalize/monetize that care
• You’re a psychiatrist (MD/DO) with clinical interest in metabolic health and willing to invest in learning obesity medicine protocols
• You’re licensed in telehealth-friendly states (FL, TX, CA, IL) where compliance pathways are clear
• You’re comfortable with the economics—either building your own marketing funnel over 6–12 months, or joining a platform like Klarity that handles patient acquisition for a per-appointment fee

You should proceed cautiously if:

• You’re a PMHNP without physician collaboration—scope-of-practice questions aren’t trivial, and state boards do investigate
• You’re licensed primarily in New York and want to prescribe phentermine—hybrid in-person/telehealth model required
• You’re not prepared for the documentation rigor—state boards reviewing telehealth obesity cases expect comprehensive work-ups, not ’15-minute video call → send Rx’
• You’re banking on insurance reimbursement—many payers don’t cover GLP-1s for weight loss, and cash-pay patients are price-sensitive

The opportunity is real: Americans spent over $80 billion on weight loss in 2023, and telehealth is the fastest-growing delivery channel. GLP-1 demand far outstrips supply of qualified prescribers. But this isn’t passive income—it’s a clinical service that requires competence, compliance, and ongoing patient management.

If you’re serious about adding weight loss to your practice, here’s your next step: Understand your state’s rules cold (use the checklist above), set up compliant documentation workflows, and decide whether you’re building your own patient pipeline or partnering with a platform that removes the acquisition risk.

Ready to Explore Telehealth Weight Loss Without the Marketing Gamble?

If you’re a psychiatrist or PMHNP interested in treating weight loss patients via telehealth—but don’t want to spend months and thousands of dollars testing marketing channels—Klarity’s provider network offers a simpler path.

Instead of paying upfront for SEO, ads, and directory listings with uncertain ROI, you join a platform where pre-qualified patients are matched to your availability and specialty. You control your schedule, set your rates, and only pay when patients book.

Learn more about joining Klarity’s provider network and skip the patient acquisition headaches: Explore Klarity for Providers

(This article is for informational purposes only and does not constitute legal or medical advice. Consult your state medical board, malpractice carrier, and legal counsel before implementing any telehealth prescribing practices.)

Sources and References

1. U.S. Department of Health & Human Services – Press Release: ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (January 2, 2026) – Official DEA/HHS policy statement on federal telehealth extension. Available at: https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Florida Statutes § 456.47 – Use of Telehealth to Provide Services (Florida Telehealth Act) (Effective 2019, accessed November 2025) – Official state statute governing telehealth practice standards and controlled substance prescribing restrictions in Florida. Available at: http://www.leg.state.fl.us/statutes/

3. Florida Administrative Code 64B8-9.012 – Standards for the Prescription of Drugs to Treat Obesity (Effective August 8, 2022) – Florida Board of Medicine regulation detailing obesity prescribing requirements including BMI thresholds, informed consent, and quarterly re-evaluation mandates. Available at: https://regulations.justia.com/states/florida/64/64b8/chapter-64b8-9/section-64b8-9-012/

4. Goodwin Law – Client Alert: ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (March 30, 2024) – Comprehensive legal analysis of state-specific obesity prescribing rules (Florida, New Jersey, Virginia) by healthcare law attorneys. Available at: https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. California Medical Association (CMA) – News: ‘GLP-1 medications for weight loss will no longer be covered by Medi-Cal’ (December 2, 2025) – Official announcement from California Department of Health Care Services regarding Medicaid coverage changes for weight-loss medications effective January 2026. Available at: https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated